Agendia Appoints Seasoned Diagnostics Executive Albert A. Luderer to Supervi... ( HUNTINGTON BEACH California and A...)

Agendia Appoints Seasoned Diagnostics Executive Albert A. Luderer to Supervisory Board

Date:3/5/2009

HUNTINGTON BEACH, California and AMSTERDAM, March 5 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced the appointment of Dr. Albert A. (Al) Luderer to its Supervisory Board.

Dr. Luderer has more than 30 years of experience in in vitro medical diagnostics, laboratory medicine and therapeutic development. Currently, he is the Chief Executive Officer and President of BioTrove, a privately held company using innovative platform technologies to dramatically increase throughput for pharmaceutical screening and genomics research, accelerating drug-discovery decisions and pipeline development. Dr. Luderer is also the Director of Light Micronics, Inc. and a Scientific Advisory Board member at Washington University's Department of Biomedical Engineering, St. Louis, MO.

"We are very pleased to welcome Al to our Supervisory Board," commented Bernhard Sixt, Ph.D., President and Chief Executive Officer of Agendia. "As we continue to expand our U.S. activities, Al's extensive experience and track record of success in the diagnostics industry will prove extremely valuable to Agendia's growth." Previously, Dr. Luderer served as Director, President and Chief Executive Officer of Light Sciences Corporation where he spearheaded the company's combined business, technical and commercial activities. Prior to joining Light Sciences Corporation, Dr. Luderer was President and Chief Operating Officer at bioMerieux, Inc., a world leader in in vitro diagnostics. From 1987 - 1993, Dr. Luderer was at Boehringer Mannheim Corporation (now Roche) where he was named Vice President of Technology Development and Support. He started his work in the sector at Corning Inc. as a key figure negotiating the joint venture diagnostic company Ciba Corning (now Siemens Healthcare Diagnostics).

Dr. Luderer holds a Bachelor of Arts from Drew University and an M.S. and Ph.D. from
'/>"/>

0

GOOD

Page: 1 2
Related biology technology :

1. Agendia Publishes Direct Evidence That MammaPrint Predicts Benefit of Chemotherapy in Breast Cancer
2. Agendia Appoints VP of Business Development
3. Agendias Breast Cancer Test MammaPrint(R) Standard of Care at Netherlands Cancer Institute - AVL
4. Agendia Appoints New Chief Financial Officer
5. Agendia and Ferrer Announce Exclusive Agreement for Sales of Cancer Diagnostic Services in Four Major European Markets
6. Agendias MammaPrint(R) Receives Prestigious Award From Dutch Innovation Platform
7. Agendia and Agilent Announce Plans to Jointly Develop New Diagnostic Tests, Extend Supply Agreement
8. Agendia BV Appoints Clinical and Scientific Advisory Board
9. Agendia BV Announces That its Chief Research Officer Laura van t Veer has Received a 2007 Breast Cancer Research Foundation Award
10. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
11. Agendia Joins the Personalized Medicine Coalition (PMC)

Post Your Comments:

Agendia Appoints Seasoned Diagnostics Executive Albert A. Luderer to Supervi...( HUNTINGTON BEACH California and A...)